tiprankstipranks
Trending News
More News >

Decibel Therapeutics reports Q3 net loss ($16.0M) vs. ($16.4M) last year

As of September 30, cash, cash equivalents and available-for-sale securities were $111.9M, compared to $162.3M as of December 31, 2021. Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its operating expenses into 2024.

Confident Investing Starts Here:

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on DBTX:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue